SEC Comment Letter for CAPRICOR THERAPEUTICS, INC. (CAPR) (CIK 0001133869) (CAPR) — Apr 18, 2006
CAPRICOR THERAPEUTICS, INC. (CAPR) (CIK 0001133869)
Date: April 18, 2006 · CIK: 0001133869 · Accession: 0000000000-06-018170
AI Filing Summary & Sentiment
File numbers found in text: 333-55166
Show Raw Text
Mail Stop 3561 April 18, 2006
Mr. James M. Charuk
President and Director
SMI Products, Inc
3503 Cedar Locust
Sugarland, TX
77479
Re: Form 10-KSB/A filed April 4, 2006
File No. 333-55166
Dear Mr. Charuk:
We have reviewed your filing and have the following comments. Where indicated, we
think you should revise your document in response to these comments. If you disagree, we will consider your explanation as to why our comment is inapplicable or a revision is unnecessary. In some of our comments, we may ask you to provide us with supplemental information so we may better understand your disclosure. After reviewing this information, we may or may not raise additional comments.
Please understand that the purpose of our review process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comments or any other aspect of our review. Feel free to call the applicable staff person at the telephone number listed at the end of this letter.
Form 10- KSB/A for the fiscal year ended December 31, 2005 filed April 4, 2006
Item 8A. Controls and Procedures
1. Please revise to include the information required by Items 307 and 308 (c) of Regulation S-B. For further guidance please refer to Commission’s interpretation release No. 33-8238: Management's Reports on Internal Control over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Report, which may be found on the
Commission’s website at
http://www.sec.gov/rules/final/33-8238.htm
Item 14. Principal Accountant Fees and Services
2. Please revise to provide the information required by Item 9(e) of Schedule 14A.
SMI Products, Inc
We urge all persons who are responsible for the accuracy and adequacy of the disclosure
in the filing reviewed by the staff to be certain that they have provided all information investors
require for an informed decision. Since the registrant and its management are in possession of all facts relating to a registrant’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.
In connection with responding to our comments, please provide, in writing, a statement
from the registrant acknowledging that:
• the registrant is responsible for the adequacy and accuracy of the disclosure in the filing;
• staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
• the registrant may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
In addition, please be advised that the Division of Enforcement has access to all information you provide to the staff of the Division of Corporation Finance in our review of your filing or in response to our comments on your filing.
Please make appropriate revisions in response to these comments. Please furnish a cover
letter with your revisions that keys your responses to our comments and provides any requested supplemental information. Detailed cover letters greatly facilitate our review. These revisions and the letter should be filed on EDGAR no later than May 9, 2006. Please understand that we may have additional comments after reviewing your revisions and responses to our comments.
You may contact Raj Rajan at (202) 551- 3388 or Hugh West at (202) 551- 3872 if you
have questions regarding comments on the financial statements and related matters.
S i n c e r e l y ,
T i a J e n k i n s
Senior Assistant Chief Accountant
Office of Emerging Growth Companies